Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight
The Sjögren's syndrome market is undergoing a notable transformation, moving beyond traditional symptomatic management toward targeted immunomodulatory therapies. Emerging candidates, including Telitacicept (Vor Biopharma), Dazodalibep (Amgen), Nipocalimab (Johnson & Johnson),...